Search

Get your pharma heroes nominated by January 12!

Can genetically engineering yeast be used to produce safe and scalable schizophrenia plant-inspired drugs?

Data is power when it comes to batch-quality prediction and obtaining the coveted perfect profile.

Our roundup of some of our thoughtful and inspiring video interviews and roundtables from the past year.

Exploring the gaps and opportunities in Canada’s cell and gene workforce.

A selection of some of the most poignant words spoken by interviewees this year

Cerevel Therapeutics' Emraclidine - in development for schizophrenia and Alzheimer’s disease psychosis - yields positive results in phase Ib trial

From flu vaccines, to gene editing, to antibody drug conjugates, and women’s careers; we look back on our 2023 magazine covers.

Exploring the potential of hybrid peptide-DNA nanostructures and artificial life

A quick look at trends in single use – plus top tips from Avantor for making the switch.